M Pfreundschuh

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

B. Hanfstein, Michael Lauseker, R Hehlmann et al. · Haematologica · 2014 · 119 citations · Full text

Medicine, Hematology, Oncology +11

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

John F. Seymour, M Pfreundschuh, Marek Trněný et al. · Haematologica · 2014 · 109 citations · Full text

Medicine, Hematology, Oncology +16

T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28

Christoph Renner, S Ohnesorge, Gerhard Held et al. · Blood · 1996 · 88 citations · Full text

Life Sciences, Cell Biology, Immunology +12

T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28

Christoph Renner, S Ohnesorge, Gerhard Held et al. · Blood · 1996 · 74 citations · Full text

Life Sciences, Cell Biology, Immunology +12

Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis

M Pfreundschuh, Lorenz Trümper, Dan Ma et al. · Journal of Clinical Oncology · 2004 · 71 citations

Medicine, Immunology, Oncology +7